Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors
We discovered 21 DMPs and developed a predictive model validated in two independent cohorts. Our model, using a distance-to-centroid approach, accurately distinguished between benign and malignant disease. This model can potentially be used in other types of sample material. Moreover, the strategy of the model development and validation can also be used in other disease contexts for diagnostic purposes.
Authors
- Colm J. O’Rourke (ORCID: https://orcid.org/0000-0002-2224-2663)
- Claus Høgdall (ORCID: https://orcid.org/0000-0002-5959-8874)
- Estrid Høgdall (ORCID: https://orcid.org/0000-0003-4689-5658)
- Jesper B. Andersen (ORCID: https://orcid.org/0000-0003-1760-5244)
- Edyta Biskup (ORCID: https://orcid.org/0000-0002-5510-2712)
- Douglas V.N.P. Oliveira (ORCID: https://orcid.org/0000-0002-3529-4219)
- Julie L. Hentze (ORCID: https://orcid.org/0000-0002-8572-2090)
Institutions
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Molecular Diagnosis & Therapy
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1007/s40291-024-00740-y
- Citations
- 4
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Københavns Universitet